Work Here?
Fractyl focuses on creating therapies for Type 2 Diabetes (T2D) and obesity, targeting the root causes of these metabolic diseases. Their main product, Rejuva, is a gene therapy platform aimed at improving the function of pancreatic islet cells, which are essential for blood sugar regulation. By enhancing these cells, Fractyl hopes to achieve long-term remission for patients with T2D and obesity. Currently, Rejuva is in preclinical development and has received a CE mark for commercial availability in Europe, although it is still awaiting full FDA approval. Unlike many competitors, Fractyl's approach emphasizes addressing the underlying mechanisms of these diseases rather than just managing symptoms. The company's goal is to transform the treatment landscape for T2D and obesity, ultimately preventing and eliminating these conditions.
Company Stage
IPO
Employees
51-200
Industries
Biotechnology, Healthcare
Total Funding
$282.2M
Headquarters
Lexington, Kentucky
Founded
2010
Help us improve and share your feedback! Did you find this helpful?
Find jobs on Simplify and start your career today